It has also been found that T cells and myeloid cells from COVID-19 patients may trigger an inflammatory storm in the lungs through intercellular communication via the ANXA1/FPR1 receptor–ligand signaling pathway [44] The study by Lee H et al. [45] also concluded that FPR1 is a suitable target for appropriate assessment of COVID-19 severity and provision of therapeutic agents. This evidence concerns the gene FPR1 and COVID-19.